Search

Researchers have submitted a patent application for a method of screening compounds to treat Central Nervous System (CNS) disorders. The method focuses on modulating GABAergic inhibition, a major inhibitory neurotransmitter in the mammalian CNS, to address conditions like epilepsy and mood disorders. The patent application outlines various techniques for screening candidate GABA receptor trafficking modulators and potentiators, emphasizing the need for new agents to treat CNS-related disorders. [Extracted from the article]

A recent study conducted at Children's Hospital in Hamilton, Canada, focused on infantile epileptic spasms syndrome (IESS) and the effects of vigabatrin treatment. The research found that mean global field power, a computational EEG biomarker, was significantly reduced in IESS patients after treatment with vigabatrin. While spike source coherence showed promise as a tool for assessing treatment responses, further studies are needed to explore its potential fully. This study highlights the importance of EEG biomarkers in diagnosing and monitoring IESS in children. [Extracted from the article]

A recent study conducted by Monash Health in Victoria, Australia, focused on the use of tissue expansion before baclofen pump insertion in pediatric patients. The research aimed to minimize complications such as pump migration, extrusion, wound dehiscence, and infection by creating a safe pocket for the pump. The study involved a case series of three pediatric patients who underwent tissue expansion, with successful outcomes reported six months after pump insertion. The research concluded that this approach offers a reliable and reproducible method for safely delivering intrathecal baclofen in the pediatric population. [Extracted from the article]

A study conducted at Mashhad University of Medical Sciences in Iran examined the correlation between the length of hospital stay and APACHE and PSS scores in cases of baclofen toxicity. The study found that there was a positive correlation between the APACHE score and the length of hospital stay in cases of baclofen alone intoxication. However, there was no correlation between PSS scores and length of hospital stay in these cases. The research provides valuable insights into the severity and management of baclofen poisoning. [Extracted from the article]

A study conducted at Children's University Hospital Nino Jesus in Madrid, Spain, focused on the use of intrathecal baclofen therapy (IBT) for spasticity and dystonia in pediatric patients with serious neurological conditions. The research involved a retrospective review of clinical records of patients who received IBT between September 2012 and February 2021. The study found that IBT led to a period of clinical stability and improved control of muscle tone disorders in patients with various conditions, including infantile cerebral palsy and neurodegenerative diseases. The findings suggest that IBT may be beneficial for managing spasticity and dystonia in pediatric patients with complex neurological conditions. [Extracted from the article]

Researchers from China Agricultural University have conducted a study on enteritis, a condition characterized by intestinal inflammation. The study focused on the role of oxidative stress in the development of intestinal inflammation and the potential effects of GABAergic signaling in reducing oxidative stress. The results showed that GABA (gamma-aminobutyric acid) could alleviate enteritis by reducing the shedding of intestinal mucosal epithelial cells, inhibiting the expression of proinflammatory factors, and enhancing the levels of anti-inflammatory cytokines. The study also found that activating GABA B receptor (GABA [B] R) strengthened antioxidant abilities by interrupting the TLR4/MyD88/NLRP3 pathway. Additionally, GABA [B] R signaling was found to contribute to reversing intestinal flora imbalances and relieving oxidative stress. This research provides new insights for the treatment of intestinal inflammation. [Extracted from the article]

A recent report from Children's Hospital in Naples, Italy discusses the use of selective dorsal rhizotomy (SDR) as an alternative to intrathecal baclofen (ITB) pump reimplantation for children with spasticity due to cerebral palsy. The study examined a cohort of six patients who had previously undergone ITB pump implantation and found that SDR was effective in reducing spasticity and improving patients' quality of life. The researchers recommend offering SDR to all children, regardless of their previous ITB pump placement. This research has been peer-reviewed and provides valuable insights into the management of spasticity in pediatric patients. [Extracted from the article]

A recent study conducted at Henry Ford Hospital focused on understanding the role of cancer-associated fibroblasts (CAFs) in pancreatic cancer. CAFs are responsible for creating an immunosuppressive environment in tumors, hindering the effectiveness of immunotherapies. The researchers found that CAFs produce high levels of glutamate, which can be converted into gamma-aminobutyric acid (GABA), a major immunosuppressive metabolite. Interestingly, the study discovered a non-canonical pathway used by CAFs to produce GABA, involving the expression of specific enzymes. Further research aims to identify the cytokine profile of CAFs and analyze tumor interstitial fluid to improve clinical outcomes for pancreatic cancer patients. [Extracted from the article]

A study conducted by researchers in the Government of India compared the efficacy of two medications, Baclofen and Diazepam, in managing spasticity following acquired spinal cord injuries. The study involved 60 patients who were randomly assigned to receive either Baclofen or Diazepam. The researchers found that Baclofen was superior to Diazepam in terms of efficacy, particularly for flexor spasticity of the lower limbs. This information may be useful for individuals seeking treatment options for spasticity resulting from spinal cord injuries. [Extracted from the article]

A study conducted by the China National Clinical Research Center for Neurological Diseases investigated the levels of gamma-aminobutyric acid (GABA) and glutamate/glutamine (Glx) in patients with New daily persistent headache (NDPH). The study used magnetic resonance spectroscopy (MRS) to analyze the neurotransmitter levels in the periaqueductal gray (PAG) and dentate nucleus (DN) of the brain. The results showed that there were no significant differences in GABA and Glx levels between NDPH patients and healthy controls. However, certain clinical scales were found to be correlated with the neurotransmitter levels, suggesting a relationship between NDPH symptoms and these levels. [Extracted from the article]

A patent application has been filed for the use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis. Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and can lead to pain, swelling, and loss of function. Current treatments for rheumatoid arthritis include disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The new treatment aims to provide an effective and potentially safer alternative for managing the symptoms of rheumatoid arthritis. [Extracted from the article]

A patent application has been submitted for the use of (S)-3-Amino-4-(Difluoromethylenyl) Cyclopent-1-Ene-1-Carboxylic Acid in the treatment of multiple sclerosis. Multiple sclerosis is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neuronal loss. Current treatments aim to decrease relapses and MRI activity, but there is a need for additional therapies with reduced side effects. The patent application proposes administering (S)-3-Amino-4-(Difluoromethylenyl) Cyclopent-1-Ene-1-Carboxylic Acid to improve symptoms of multiple sclerosis. [Extracted from the article]

Researchers at the National Rehabilitation Hospital have published a case report on the use of intrathecal baclofen for a patient with neurofibromatosis-related spinal cord injury and spasticity. The patient, a 35-year-old male, experienced lower limb weakness and severe spasticity, requiring assistance for daily activities. After a successful trial of intrathecal baclofen and subsequent implantation of a pump, the patient's muscle tone improved, and he achieved independence in transfers and most activities of daily living. This case report highlights the potential benefits of intrathecal baclofen for individuals with neurofibromatosis-related spinal cord injury and spasticity. [Extracted from the article]

A recent study conducted by researchers at KIIT University in Odisha, India compared the effectiveness of two medications, carbamazepine and baclofen, in managing trigeminal neuralgia. The study involved 100 patients with trigeminal neuralgia, who were randomly divided into two groups. The results showed that both medications had similar success rates in treating the condition, and the incidence of adverse effects was also similar between the two groups. This research provides valuable insights into the medical management of trigeminal neuralgia and may help inform treatment decisions for patients suffering from this condition. [Extracted from the article]

A recent report from Amasya University in Turkey discusses the increasing interest in gamma-aminobutyric acid (GABA), which is produced by lactic acid bacteria (LABs). GABA is a non-protein amino acid that is used in the food industry to improve food safety and quality. The report highlights the potential positive effects of GABA on neuroprotection, sleep quality, depression, pain relief, and various health benefits such as antidiabetic, antihypertensive, and anti-inflammatory effects. The study also mentions ongoing efforts to identify LAB strains with high GABA productivity and increase GABA production through genetic engineering. However, the full contributions of GABA to food safety, quality, and human health have not been fully explored, leaving room for further research. [Extracted from the article]

A recent report discusses research on neuromyelitis optica (NMO), a neurological disorder that affects the central nervous system. The study focused on the association between neurotransmitter imbalances and cognitive deficits in NMO patients. The researchers used magnetic resonance spectroscopy to evaluate levels of gamma-aminobutyric acid (GABA), glutamate, and glutathione in different regions of the brain. The results showed that NMO patients had decreased GABA levels and increased glutamate, glutathione, and excitation/inhibition ratio in certain brain regions. These findings suggest that dysregulation in the GABAergic and glutamatergic systems may contribute to emotional disorders and cognitive decline in NMO patients. The study also highlights the potential benefits of reducing oxidative stress to protect cognitive function in these patients. [Extracted from the article]

A recent report from Gedeon Richter researchers in Budapest, Hungary, discusses their investigation into the social behavior of the Fawn-hooded rat strain, which is often used as a model for various disorders. The study found that the rats exhibited impaired social behavior, including reduced social play and impaired social novelty discrimination. They also displayed heightened tactile sensitivity and hyperactivity, similar to the effects of prenatal valproate exposure, a model of autism spectrum disorder. The researchers discovered that treatment with the pro-social drug R-baclofen reversed these autistic-like behaviors in the rats, suggesting that this strain could serve as a model for autism and aid in the development of new drug candidates. [Extracted from the article]

A new report from the Cleveland Clinic Foundation provides insights into the rate and risk factors of complications associated with intrathecal baclofen (ITB) therapy in adults. The study found that 27% of patients experienced ITB-related complications, with the most common being infection, pump malfunction, and catheter malfunction. The analysis revealed that ambulatory status at the time of pump implantation and the number of years since surgery were significant factors in the likelihood of developing complications. The research contributes valuable information for physicians in guiding patient selection for ITB therapy. [Extracted from the article]

A recent study conducted at Sultan Qaboos University Hospital highlights the potential neurotoxicity of baclofen in patients undergoing dialysis. Baclofen, a commonly prescribed drug for spasticity, hiccups, and multiple sclerosis, relies on renal excretion, making individuals with impaired kidney function more susceptible to toxicity. The study emphasizes the lack of clear guidelines regarding baclofen safety and dose adjustments for patients with kidney disease, calling for increased awareness and careful consideration of its use in this population. The research provides a comprehensive review of existing literature on baclofen toxicity in cases of renal insufficiency. [Extracted from the article]

A recent study conducted by researchers at Udayana University in Bali, Indonesia, has explored the potential use of gamma-aminobutyric acid (GABA) in delaying the onset of type 1 diabetes mellitus (T1DM) in children. The current standard treatment for T1DM is insulin therapy, which can lead to complications. The study found that GABA has protective and proliferative effects on beta cells and immune cells, which are involved in T1DM. Various in vitro and in vivo studies have shown that GABA can increase insulin levels, inhibit beta-cell apoptosis, and suppress immune cell activity against islet antigens. The use of oral GABA was found to be safe with no serious adverse effects reported. The findings suggest that GABA treatment shows promise in delaying T1DM, particularly in genetically predisposed children, through its immunoregulatory effects and ability to induce beta-cell proliferation. [Extracted from the article]

A recent study conducted in Chicago, Illinois, explored the safety and efficacy of using a cervical catheter tip for the continuous intrathecal baclofen (ITB) treatment of hypertonia in children. Traditionally, the cervical tip location has been avoided due to concerns of hypoventilation and pneumonia, but this study found that these complications were not reliably proven. The study included 25 patients, and the results showed that the cervical catheter tip location for ITB is safe and effective in controlling tone. However, larger studies with longer follow-up are needed to determine upper-limit dosing safety and long-term functional benefits. [Extracted from the article]

A systematic review conducted by researchers at the University of Cambridge evaluated the effectiveness of intrathecal baclofen (ITB) in treating multiple sclerosis-related spasticity (MSRS). The review analyzed studies published between 2000 and 2023 and found evidence supporting the effectiveness of ITB in treating MSRS patients who did not respond to oral medications. The treatment was shown to reduce spasm frequency and improve patients' quality of life. Complications were primarily surgical rather than pharmacological, and the average 1-year dose of ITB was lower than doses reported for other conditions. The review concludes that ITB is a clinically effective treatment for MSRS when other treatments have failed. [Extracted from the article]

A patent application has been submitted for stable oral baclofen compositions, which are used to treat spasticity in conditions like multiple sclerosis or spinal cord injury. The current forms of baclofen have limitations, so the application aims to develop stable liquid suspensions that can be easily administered orally and have a long shelf life. These suspensions would be beneficial for pediatric and geriatric patients, providing dosing flexibility. The patent application describes the specific elements and concentrations of the composition, as well as its stability and low impurity level. It also includes claims for the composition and its use in treating spasticity. [Extracted from the article]

A study conducted by researchers at Kyoto Prefectural University of Medicine in Japan explored the treatment of basilar invagination (BI) with Klippel-Feil syndrome (KFS), a condition characterized by the fusion of cervical vertebrae. The study focused on a 16-year-old boy with severe BI and KFS who underwent posterior occipitocervical reduction and fusion surgery, followed by intrathecal baclofen (ITB) therapy. The combination of surgery and ITB treatment effectively improved the patient's condition, reducing spasticity and enabling improved activities of daily life. The study highlights the potential benefits of this treatment approach for patients with BI and congenital anomalies. [Extracted from the article]

A case report from the University of Florida discusses the management of a 62-year-old woman with severe tetanus. The report focuses on the use of intrathecal baclofen (ITB) therapy, which was administered after oral baclofen failed to control the patient's spasms. The report highlights the benefits of ITB in reducing spinal cord reflexes and managing severe spasticity. Despite initial complications, the patient was effectively treated and discharged. The report emphasizes the importance of interdisciplinary collaboration and tailored approaches to achieve the best patient outcomes. [Extracted from the article]

A recent report from Radboud University Medical Center in the Netherlands highlights a potentially life-threatening interaction between opioids and intrathecal baclofen (ITB) in individuals with childhood-onset neurological disorders. The study describes four cases where patients experienced central nervous system (CNS) depression and overdose symptoms after using ITB and opioids together. The researchers recommend close monitoring of patients using these medications together to detect interaction symptoms early and reduce the risk of severe complications. Further research is needed to fully understand the mechanisms of this interaction. [Extracted from the article]

A recent study conducted by Yonsei University in Seoul, South Korea compared the effectiveness and safety of baclofen and gabapentin in reducing leg pain from nocturnal calf cramps in patients with lumbar spinal stenosis. The study found that both medications significantly reduced leg pain, calf cramp frequency and intensity, and insomnia severity index scores. However, the baclofen group also showed a significant decrease in functional disability, while the gabapentin group did not. The study concluded that baclofen is as effective and safe as gabapentin in treating nocturnal calf cramps in patients with lumbar spinal stenosis, and may even have superior functional outcomes. [Extracted from the article]

A recent report published in the Annals of Indian Psychiatry discusses the evolving use of Baclofen, a medication primarily used as an anti-spastic agent, as an off-label treatment for Alcohol Use Disorders. However, the report highlights the increased risk of abuse associated with Baclofen's relaxant properties. The researchers emphasize the importance of being suspicious when encountering patients with Alcohol Use Disorders who exhibit unexplained symptoms of central nervous system depression. The report presents a case study of a patient with alcoholic dependence syndrome who presented in an unconscious state after ingesting Baclofen and alcohol. [Extracted from the article]

A research study conducted by the Karnataka Institute of Medical Sciences in India compared the effects of two amino acids, Gamma-aminobutyric acid (GABA) and L-theanine, on sedation, anxiety, and cognition in preoperative surgical patients. The study found that both GABA and L-theanine effectively reduced preoperative anxiety with minimal sedation and improved cognitive skills. The researchers suggest that these amino acids could be alternative premedicants to benzodiazepines, which can impair psychomotor performance and cause excessive sedation. This study provides new insights into the potential benefits of GABA and L-theanine in managing anxiety disorders. [Extracted from the article]

A recent report from the Universidade Federal do Parana in Brazil discusses the case of a 5-month-old girl with developmental delay and epileptic spasms. The girl was diagnosed with West Syndrome (WS) and was treated with vigabatrin therapy, which led to reversible MRI signal changes. However, the patient also developed drug-induced dyskinesia, a hyperkinetic movement disorder. Further investigation revealed a genetic mutation in the ALG13 gene. This case highlights the challenges in diagnosing and understanding WS and emphasizes the importance of a thorough work-up to determine the underlying genetic cause. [Extracted from the article]

A new study conducted by researchers at Tehran University of Medical Sciences has found that intrathecal baclofen (ITB) therapy can significantly reduce spasticity in patients with cerebral palsy. The study, which involved a systematic review and meta-analysis of multiple studies, found that ITB therapy led to a 40.25% reduction in spasticity scores. Additionally, there was a small but statistically significant improvement in motor function in the patients. However, the study also noted that there were some medical complications associated with ITB therapy, including seizures, infections, and cerebrospinal fluid leaks. [Extracted from the article]

Researchers from National Cheng Kung University in Tainan, Taiwan have made recent findings on gamma-Aminobutyric Acid (GABA) production in Escherichia coli. They have developed a novel regulatory tool that utilizes the interplay between glutamate decarboxylase and tryptophan operons to optimize GABA production. The study demonstrates the potential of acid/base regulation mediated by gad and tna operons as a toggle switch and control element for enhancing GABA production. This research has been peer-reviewed and provides valuable insights into the production of GABA. [Extracted from the article]

A recent study conducted by researchers at Universite Paris Cite in France focused on optimizing the dosage of vigabatrin, an antiepileptic drug used to treat severe epilepsy in children. The study aimed to identify an acceptable exposure range for the drug by developing a population pharmacokinetic model and studying therapeutic response. The researchers analyzed data from 79 patients and found that bodyweight and creatinine clearance were the main factors explaining the variability of vigabatrin. The study concluded that a target concentration intervention approach using this pharmacokinetic model could help avoid overexposure in responder patients. [Extracted from the article]

A recent study conducted at the Federal University Sao Paulo in Brazil explored the potential use of gold nanoparticles in the diagnosis and treatment of breast cancer. The researchers found that gold nanoparticles capped with aminolevulinic acid (ALA), methyl aminolevulinate (MALA), and gamma-aminobutyric acid (GABA) showed promise in low-energy X-ray diagnostics and therapy for breast cancer. These nanoparticles were able to reduce cell viability and enhance contrast, making them a potential material for breast cancer diagnosis and treatment. The study was funded by the National Institute of Science and Technology Complex Fluids (INCT-FCX) and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). [Extracted from the article]

A research study conducted at Seoul National University in South Korea investigated the effects of baclofen on central positional nystagmus (CPN), a condition characterized by involuntary eye movements. The study involved 15 patients with paroxysmal downbeat CPN who were given baclofen for at least one week. The results showed that baclofen significantly reduced the intensity of CPN, as measured by slow phase velocity (SPV), and also decreased positional vertigo. However, these effects were reversed after discontinuation of baclofen. The study suggests that baclofen may be a potential treatment option for symptomatic patients with paroxysmal CPN. [Extracted from the article]

New research from Kasetsart University in Bangkok, Thailand explores the role of gamma-aminobutyric acid (GABA) in the gut-brain axis and its potential as a mediator for mental health. GABA is an inhibitory neurotransmitter that plays a crucial role in the central nervous system. Imbalances of GABA have been associated with neurological diseases and psychological disorders. The study suggests that changes in GABA levels and gut microbiota composition may play a significant role in modulating mental health. Further research on GABA production-inducing microorganisms and food factors as potential treatments for neurological and psychological disorders is recommended. [Extracted from the article]

Researchers from the University of Baghdad have conducted a study on the role of gamma-aminobutyric acid (GABA) and insulin regulated aminopeptidase (IRAP) in insulin resistance and glucose transport type 4 (GLUT4) in prediabetes and type 2 diabetes mellitus. The study involved 90 individuals divided into three groups (diabetics, prediabetics, and healthy individuals) and measured various factors such as glycated hemoglobin, serum glucose, serum insulin, GABA, IRAP, and GLUT4. The results showed that decreased levels of GABA may promote insulin resistance and the onset of prediabetes and diabetes, while decreased levels of IRAP suggest a role in glucose uptake. This research provides valuable insights into the mechanisms of insulin resistance and may help in identifying individuals at risk for prediabetes. [Extracted from the article]

A recent study conducted by researchers at the University of Alberta in Canada examined the role of glutamate (Glu) and gamma-aminobutyric acid (GABA) in the medial prefrontal cortex (MPFC) in major depression (MD). The study found that there were no significant differences in Glu and GABA levels between women with MD and healthy controls when reproductive status was taken into account. However, the researchers noted that the limitations of the study's methodology do not rule out the possibility of glutamatergic and GABAergic dysregulations in the MPFC of women with MD. This research provides valuable insights into the understanding of depression and its potential underlying mechanisms. [Extracted from the article]

Pyros Pharmaceuticals has announced that their drug VIGPODER(TM) (vigabatrin) is now available. However, it is important to note that VIGPODER(TM) can cause permanent vision loss, including tunnel vision and decreased visual acuity. The risk of vision loss increases with higher doses and cumulative exposure, and there is no known dose that is free of this risk. Patients on VIGPODER(TM) should undergo baseline and periodic vision assessments, although these assessments may not always prevent vision damage. The drug is only available through a restricted program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Additionally, VIGPODER(TM) may cause abnormal MRI signal changes and intramyelinic edema in some infants and young children, but these changes generally resolve with discontinuation of treatment. Patients should not abruptly stop VIGPODER(TM) therapy to avoid withdrawal seizures, and should be monitored for symptoms of anemia. The drug may also cause somnolence and fatigue. [Extracted from the article]

A recent study conducted at Sankara Eye Hospital in Tamil Nadu, India, explored the use of electroretinogram (ERG) as a screening tool for vigabatrin-induced retinal toxicity in children with infantile spasms. The study included 11 children with infantile spasms who were receiving treatment with vigabatrin. The results showed that 72.7% of the children exhibited vigabatrin-induced retinal toxicity, and the duration of treatment was found to be a significant factor in the development of retinal toxicity. The study suggests that ERG can be used to monitor retinal toxicity in children with infantile spasms. [Extracted from the article]

Researchers at Wenzhou Medical University in China have conducted a study on hepatic ischemia/reperfusion injury (HIRI), a common factor in poor prognosis for liver diseases. The study found that metformin, a medication commonly used to treat diabetes, can alleviate HIRI by reshaping the gut microbiota in mice. This reshaping leads to an increase in gamma-aminobutyric acid (GABA) producing bacteria, which has a beneficial effect on HIRI-induced ferroptosis. The study suggests that metformin may be a potential treatment for HIRI, and GABA could be a key metabolite in this process. [Extracted from the article]

A study conducted at Shahed University in Tehran, Iran, has found that morphine can induce ovarian cysts in female rats, leading to obesity and disruption of sex hormone secretion. However, the study also discovered that baclofen, a gamma-aminobutyric acid receptor agonist, can protect against morphine-induced inhibition and regulate sex hormones, as well as reduce harmful blood lipids. The research concluded that baclofen prophylaxis can protect reproductive properties by adapting major metabolic changes. This study provides valuable insights into the potential protective effects of baclofen on ovarian cystogenesis and morphine-induced lipid profile changes. [Extracted from the article]

A recent study conducted by researchers from Soochow University in Suzhou, China, explored the relationship between plasma amino acid neurotransmitters and the prognosis of ischemic stroke. The study involved 3,486 patients from 26 hospitals across China and found that increased levels of glutamic acid, aspartic acid, and gamma-aminobutyric acid, as well as decreased levels of glycine, were associated with adverse outcomes after ischemic stroke. These findings suggest that plasma amino acid neurotransmitters could be potential targets for interventions to improve the prognosis of ischemic stroke. The study was supported by the National Natural Science Foundation of China. [Extracted from the article]

A study conducted at Xinjiang Uygur Autonomous Region People's Hospital in Urumqi, China, aimed to investigate the effects of comfort interventions combined with drugs on serum 5-hydroxytryptamine and gamma-aminobutyric acid levels in patients with neurological tinnitus. The study involved 100 patients with neurological tinnitus, who were divided into an experimental group and a reference group. The experimental group received additional comfort interventions in addition to conventional medication, while the reference group received conventional medication and an audio information therapy device. The results showed that the experimental group had lower disability scores, lower serum 5-hydroxytryptamine levels, higher gamma-aminobutyric acid levels, and improved coping style and sleep quality compared to the reference group. The study concluded that comfort intervention combined with drugs is effective in improving disability in neurological tinnitus patients and is worth promoting. [Extracted from the article]

A case study conducted at University Hospital in Yvoir, Belgium, has found that the use of a personal digital tablet with a magnetic shell can cause motor shutdown in patients with intrathecal baclofen pumps. The study focused on a tetraplegic patient who experienced increased spasticity each time they used a tablet with a magnetic shell. The symptoms resolved after the removal of the protective shell. The researchers recommend that patients with intrathecal baclofen pumps avoid close contact with magnetic devices and suggest further studies to assess the effect of new magnetic technologies on the function of these pumps. [Extracted from the article]